Specialty diagnostics company Precipio, Inc. (NASDAQ: PRPO), announced today that it has completed the non-cash transaction of the transition of Oncometrix’s customer base, as discussed in Precipio’s recent announcement. As stated previously, the transaction with Poplar involves no exchange of cash or equity in consideration, providing non-dilutive impact to shareholders. “We are delighted to complete this transaction and partner with Precipio for the hematopathology business, enabling us to focus on our other core businesses”, said James Sweeney, CEO of Poplar Healthcare. “We look forward to continued collaboration with Precipio in other areas of our partnership”.
Read the full article: Precipio Completes Transaction with Poplar Healthcare’s Oncometrix Hematopathology Division //
Source: https://www.globenewswire.com/news-release/2020/03/16/2001135/0/en/Precipio-Completes-the-Transaction-with-Poplar-Healthcare-s-Oncometrix-Hematopathology-Division.html